Abstract
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the gold standard for lung cancer staging and the diagnosis of mediastinal lesions. Until 2025, this technology was unavailable in Paraguay. Objective: To describe the clinical characteristics, diagnostic yield, and safety of the first cohort of patients undergoing EBUS-TBNA for mediastinal lymph nodes. Methods: We conducted a retrospective, observational, descriptive study including the first 24 consecutive patients who underwent EBUS-TBNA at a national referral center between December 2025 and June 2026. Demographic, clinical, procedural, sample adequacy, and complication data were analyzed. Results: Twenty-four patients were included (median age, 60 years), of whom 62.5% were women. The main indication was the diagnosis of mediastinal masses or metastatic disease (91.7%), most frequently at lymph node stations 4R and 7. ROSE identified malignant specimens in 70.8% of cases, while histopathology confirmed adequate sampling in 87.5%. Lung adenocarcinoma was the most frequent diagnosis (41.7%), with no immediate complications or major adverse events observed within 30 days. Conclusion: The introduction of EBUS-TBNA in Paraguay was feasible and safe, representing a milestone for interventional pulmonology in the country.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Revista Cirugía Paraguaya